title: Drug approvals in India - Authors' reply.
authors.affiliation: Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India. Electronic address: dratulluthra@gmail.com.
authors.forename: Atul
authors.initials: A
authors.lastname: Luthra
authors.affiliation: Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India; Diabetic Foundation, New Delhi, India; National Diabetes, Obesity, and Cholesterol Foundation, New Delhi, India.
authors.forename: Anoop
authors.initials: A
authors.lastname: Misra
mesh_terms: D001599:Berberine / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D004345:Drug Industry; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D040541:Marketing; D010666:Phenylpropionates / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D010666:Phenylpropionates; D011758:Pyrroles; D001599:Berberine; D006886:Hydroxychloroquine